Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Knockdown of PLAGL2 inhibits oral squamous cell carcinoma cell growth and cisplatin resistance via ZEB1/PD-L1 pathway

Changqing Zhang, Fei Ye

Department of Stomatology, Wuhan Hankou Hospital, Wuhan City, Hubei Province 430012, China;

For correspondence:- Fei Ye Email: fei_y75@163.com Tel:+8602782283384

Accepted: 18 December 2022 Published: 30 January 2023

Citation: Zhang C, Ye F. Knockdown of PLAGL2 inhibits oral squamous cell carcinoma cell growth and cisplatin resistance via ZEB1/PD-L1 pathway. Trop J Pharm Res 2023; 22(1):45-51 doi: 10.4314/tjpr.v22i1.7

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effects of pleomorphic adenoma gene like-2 (PLAGL2) on oral squamous cell carcinoma (OSCC).

Methods: The effects of PLAGL2 on OSCC (CAL-27 and HSC-3) were conducted with loss- and gain-functional assays. Cell proliferation was determined by Cell Counting Kit-8 (CCK8) and colony formation assays. Cell metastasis was assessed by Transwell and wound healing assays. Cell apoptosis of cisplatin-resistant OSCC was evaluated by flow cytometry.

Results: PLAGL2 expression was significantly elevated in OSCC (p < 0.001), while silencing of PLAGL2 significantly reduced cell proliferation and metastasis of OSCC (p < 0.001). However, overexpression of PLAGL2 promoted OSCC progression through increase in cell proliferation, invasion, and migration. Knockdown of PLAGL2 promoted cell apoptosis of -resistant OSCC, but significantly downregulated protein expression of programmed cell death ligand 1(PD-L1) and zinc finger E-box-binding homeobox 1 (ZEB1) in OSCC (p < 0.01). Moreover, loss of ZEB1 attenuated the PLAGL2 overexpression-induced increase in ZEB1 and PD-L1. Loss of PLAGL2 also reduced in vivo tumor growth of OSCC via regulation of cluster of differentiation 4 protein (CD4) and CD8.

Conclusion: Knockdown of PLAGL2 exerts anti-tumor effects, improves cisplatin resistance, and enhances anti-tumor immunity in OSCC through suppression of ZEB1/PD-L1 pathway. Thus, PLAGL2 might be a potential therapeutic target for the treatment of OSCC.

Keywords: PLAGL2, Oral squamous cell carcinoma (OSCC), Cell proliferation, Metastasis, Tumor immunity, ZEB1, Programmed cell death ligand 1